Memorial Hospital Research Laboratories
The Liang Deng Lab
Research
Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma.
Research Projects
Featured News
Publications
Yang, N., J.M. Luna, P. Dai, Y. Wang, C.M. Rice, and L. Deng (2020) Lung type II epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against an acute vaccinia infection in the lungs. BioRxiv 10.1101/2020.01.20.910927.
Shaw K.S., G.H. Nguyen, M. Lacouture, and L. Deng. (2017). Combination of imiquimod with cryotherapy for the treatment of penile intraepithelial neoplasia. JAAD Case Rep. 3(6):546-549.
Dai, P., W. Wang, N. Yang, C. Serna-Tamayo, J.M. Ricca, D. Zamarin, S. Shuman, T. Merghoub, J.D. Wolchok, and L. Deng. (2017). Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent DCs. Science Immunology 2, eaal1713: 1-15.
Gao, P., T. Zillinger, W. Wang, M. Ascano, P. dai, G. Hartmann, T. Tuschl, L Deng, W. Barchet, and D.J. Patel. (2014). Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep 8:1-9.
Dai, P., W. Wang, H. Cao, F. Avogadri, L. Dai, I. Drexler, J. A. Joyce, T. Merghoub, S. Shuman, and L. Deng. Modified vaccinia virus Ankara triggers type I IFN production in conventional dendritic cells via a cGAS/STING-dependent cytosolic DNA-sensing pathway. PLoS Pathogens 2014;10:e1003989.
People
Liang Deng, MD, PhD
- Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.
- dengl@mskcc.org
- Email Address
- 646-888-6011
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Liang Deng discloses the following relationships and financial interests:
-
Aduro Biotech, Inc
Intellectual Property Rights
-
Imvaq Therapeutics
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.